E-ISSN 2231-3206 | ISSN 2320-4672
 

New Drug Update 


Alirocumab—a novel drug for familial hypercholesterolemia

Priyanka Kamath, Preethi J Shenoy.

Abstract
Familial hypercholesterolemia (FH) is a genetically transmitted condition, wherein abnormally high levels of total cholesterol and low density lipoproteins (LDL) are seen. Occurrence of premature cardiovascular complications is common, resulting in significant morbidities and fatalities. Currently statins are the first-choice drugs to treat FH, given alone, or in combination with other lipid lowering drugs. Alirocumab is a monoclonal antibody directed against PCSK9, a ‘gain-of-function’ mutation of which is thought to be responsible for the defective processing of LDL cholesterol, resulting in lesser uptake of LDL-C into the hepatocytes. It was approved by the US-FDA in July 2015 as a first-in-class drug, “for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.” It has to be administered subcutaneously every 2 weeks, and the dose is titrated as per need. Injection-site reactions, myalgia, neurocognitive events, pruritus were the major adverse effects observed during clinical trials. Inhibition of PCSK 9 is a new promising target for the treatment of patients with familial hypercholesterolemia.

Key words: Alirocumab, familial hypercholesterolemia, PCSK 9 inhibition


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Priyanka Kamath
Articles by Preethi J Shenoy
on Google
on Google Scholar


REFERENCES
1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004;160:421-9. [DOI via Crossref]    [Pubmed]   
2. Blom DJ. Familial hypercholesterolaemia. JEMDSA 2011;16(1): 17-24.
3. Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Card 2014;7:107-17. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
4. Hovingh GK, Davidson MH, Kastelein JJP, O’Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34:962-71. [DOI via Crossref]    [Pubmed]   
5. Robinson JG. Management of familial hypercholesterolemia: areview of the recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Manag Care Pharm 2013;19(2):139-49. [DOI via Crossref]   
6. Farniera M, Bruckert E. Severe familial hypercholesterolaemia: current and future management. Arch Cardiovas Dis 2012;105:656-65. [DOI via Crossref]    [Pubmed]   
7. Pitts RN, Eckel RH. The emerging role of PCSK9 inhibitors in preventive cardiology. EurCardiol Rev 2014;9(2):65-70. [DOI via Crossref]   
8. Gencera B, Lambert G, Mach F. PCSK9 inhibitors. Swiss Med Wkly 2015;145:w14094. [DOI via Crossref]   
9. Kuhnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res 2014;55:2103-12. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
10. Fda.gov [Internet]. Maryland: US Food and Drug Administration; [updated 2015 July 24, cited Nov 19, 2015]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm.
11. Chan JCY, Piper DE, Cao Q, Liu D, King C, Wang W,et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. ProcNatlAcadSci USA 2009;106:9820-5. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
12. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366(12):1108-18. [DOI via Crossref]    [Pubmed]   
13. Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of Alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther 2014;32:297-301. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
14. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36. [DOI via Crossref]   
15. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900. [DOI via Crossref]    [Pubmed]   
16. Kastelein JJP, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther 2014;28:281-9. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
17. Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg):design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol 2014;37(10):597-604. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
18. Roth EM, Taskinen M, Ginsberg HN, Kastelein JJP, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol 2014;176:55-61. [DOI via Crossref]    [Pubmed]   
19. Regeneron.com [Internet]. New York: Regeneron Pharmaceuticals, Inc.; [updated 2015 July, cited Nov 19, 2015]. Available at: http://www.regeneron.com/Praluent/Praluent-fpi.pdf.
20. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489-99. [DOI via Crossref]    [Pubmed]   
21. Kastelein JJP, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36:2996-3003. [DOI via Crossref]   
22. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 2015;169(6):906-15. [DOI via Crossref]    [Pubmed]   
23. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBOII randomized controlled trial.Eur Heart J 2015;36:1186-94. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
24. Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. JClinLipidol 2014;8:554-61. [DOI via Crossref]   
25. Bays H,Gaudet D,Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 2015;100(8):3140-8. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
26. Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia: introduction. In: Brunton LL, Chabner BA, Knollmann BC (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th ed. New Delhi: McGraw-Hill, 2011. pp. 876-904.
27. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. N Engl J Med 2015;373(17):1588-91. [DOI via Crossref]    [Pubmed]   
28. Zhang X, Zhu Q, Zhu L, Chen J, Chen Q, Li G, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015;13:123. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
29. Nice.org.uk [Internet]. London: National Institute for Health and Care Excellence; [updated 2008 August 27, cited 2015 Nov 19]. Available at: https://www.nice.org.uk/guidance/cg71/resources/familial-hypercholesterolaemia-identification-and-management-975623384005.
30. Sanofi and Regeneron Announce FDA Approval of Praluent® (Alirocumab) Injection, the First PCSK9 Inhibitor in the US, for the Treatment of High LDL Cholesterol in Adult Patients. [updated July 24, 2015. cited March 17, 2016]. Available at: http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_and_regeneron_announce__1941221_24-07-2015!21_24_28.aspx#

How to Cite this Article
Pubmed Style

Priyanka Kamath, Preethi J Shenoy. Alirocumab—a novel drug for familial hypercholesterolemia. Natl J Physiol Pharm Pharmacol. 2016; 6(4): 345-348. doi:10.5455/njppp.2016.6.02032016135


Web Style

Priyanka Kamath, Preethi J Shenoy. Alirocumab—a novel drug for familial hypercholesterolemia. https://www.njppp.com/?mno=220966 [Access: January 04, 2023]. doi:10.5455/njppp.2016.6.02032016135


AMA (American Medical Association) Style

Priyanka Kamath, Preethi J Shenoy. Alirocumab—a novel drug for familial hypercholesterolemia. Natl J Physiol Pharm Pharmacol. 2016; 6(4): 345-348. doi:10.5455/njppp.2016.6.02032016135



Vancouver/ICMJE Style

Priyanka Kamath, Preethi J Shenoy. Alirocumab—a novel drug for familial hypercholesterolemia. Natl J Physiol Pharm Pharmacol. (2016), [cited January 04, 2023]; 6(4): 345-348. doi:10.5455/njppp.2016.6.02032016135



Harvard Style

Priyanka Kamath, Preethi J Shenoy (2016) Alirocumab—a novel drug for familial hypercholesterolemia. Natl J Physiol Pharm Pharmacol, 6 (4), 345-348. doi:10.5455/njppp.2016.6.02032016135



Turabian Style

Priyanka Kamath, Preethi J Shenoy. 2016. Alirocumab—a novel drug for familial hypercholesterolemia. National Journal of Physiology, Pharmacy and Pharmacology, 6 (4), 345-348. doi:10.5455/njppp.2016.6.02032016135



Chicago Style

Priyanka Kamath, Preethi J Shenoy. "Alirocumab—a novel drug for familial hypercholesterolemia." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 345-348. doi:10.5455/njppp.2016.6.02032016135



MLA (The Modern Language Association) Style

Priyanka Kamath, Preethi J Shenoy. "Alirocumab—a novel drug for familial hypercholesterolemia." National Journal of Physiology, Pharmacy and Pharmacology 6.4 (2016), 345-348. Print. doi:10.5455/njppp.2016.6.02032016135



APA (American Psychological Association) Style

Priyanka Kamath, Preethi J Shenoy (2016) Alirocumab—a novel drug for familial hypercholesterolemia. National Journal of Physiology, Pharmacy and Pharmacology, 6 (4), 345-348. doi:10.5455/njppp.2016.6.02032016135